SCHEMBL5148147

SCHEMBL5148147

O=C(NCc1ccco1)c1ccc2cncc(NCc3cccnc3)c2n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.52
KMT2A Q03164 6/20 0.52
MEN1 O00255 5/20 0.52
TDP1 Q9NUW8 2/20 0.52
KDM4E B2RXH2 4/20 0.48
HTT P42858 3/20 0.48
PKM P14618 2/20 0.48
NPC1 O15118 1/20 0.48
ADORA2A P29274 2/20 0.47
ADORA1 P30542 2/20 0.47
ADORA3 P0DMS8 1/20 0.47
ADORA2B P29275 1/20 0.47
ALOX15 P16050 1/20 0.46
KDM6B O15054 1/20 0.46
KDM4A O75164 1/20 0.46
KDM5C P41229 1/20 0.46
KDM4D Q6B0I6 1/20 0.46
KDM4C Q9H3R0 1/20 0.46
MAPK1 P28482 2/20 0.44
MMP13 P45452 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4581576 0.85 ALDH1A1 (0.53) ALDH1A1KMT2AMEN1TDP1KDM4E
SCHEMBL4580503 0.81 ALDH1A1 (0.52) ALDH1A1KMT2AMEN1TDP1KDM4E
SCHEMBL4581196 0.81 ALDH1A1 (0.60) ALDH1A1KMT2AMEN1TDP1KDM4E
SCHEMBL14287188 0.80 HTT (0.41) ALDH1A1KMT2AMEN1KDM4EHTT
SCHEMBL4582783 0.80 KDM4E (0.49) ALDH1A1KMT2AMEN1KDM4EKDM6B
SCHEMBL4579023 0.80 ALDH1A1 (0.50) ALDH1A1KMT2AMEN1TDP1KDM4E
SCHEMBL4581093 0.79 KDM4E (0.58) ALDH1A1KMT2AMEN1TDP1KDM4E
SCHEMBL14266821 0.78 ALDH1A1 (0.55) ALDH1A1KMT2AMEN1TDP1HTT
SCHEMBL4580889 0.78 MAPT (0.59) ALDH1A1KMT2AMEN1TDP1KDM4E
SCHEMBL4581265 0.77 ALDH1A1 (0.53) ALDH1A1KMT2AMEN1TDP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080032991-A1 2, 8-disubstituted Naphthyridine Derivatives SERENEX, INC. 2008-02-07 US disclosed
US-7282506-B2 2,8-disubstituted naphthyridine derivatives SERENEX, INC. (US) 2007-10-16 US disclosed
US-7282506-B2 2,8-disubstituted naphthyridine derivatives SERENEX, INC. (US) 2007-10-16 US disclosed
US-7282506-B2 2,8-disubstituted naphthyridine derivatives SERENEX, INC. (US) 2007-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080032991-A1 2, 8-disubstituted Naphthyridine Derivatives CCNA1, FOXM1, CCNA2 ALDH1A1 107/4885KMT2A 2613/4885MEN1 2217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.